Literature DB >> 32336563

Clinical Consensus Recommendations Regarding Non-Invasive Respiratory Support in the Adult Patient with Acute Respiratory Failure Secondary to SARS-CoV-2 infection.

César Cinesi Gómez1, Óscar Peñuelas Rodríguez2, Manel Luján Torné3, Carlos Egea Santaolalla4, Juan Fernando Masa Jiménez5, Javier García Fernández6, José Manuel Carratalá Perales7, Sarah Béatrice Heili-Frades8, Miquel Ferrer Monreal9, José M de Andrés Nilsson10, Eva Lista Arias11, Juan Luis Sánchez Rocamora12, José Ignacio Garrote13, Miguel J Zamorano Serrano14, Mónica González Martínez15, Eva Farrero Muñoz16, Olga Mediano San Andrés17, Gemma Rialp Cervera18, Arantxa Mas Serra19, Gonzalo Hernández Martínez20, Candelaria de Haro López21, Oriol Roca Gas22, Ricard Ferrer Roca23, Antonio Romero Berrocal24, Carlos Ferrando Ortola25.   

Abstract

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, that was first recognized in Wuhan, China, in December 2019. Currently, the World Health Organization (WHO) has defined the infection as a global pandemic and there is a health and social emergency for the management of this new infection. While most people with COVID-19 develop only mild or uncomplicated illness, approximately 14% develop severe disease that requires hospitalization and oxygen support, and 5% require admission to an intensive care unit. In severe cases, COVID-19 can be complicated by the acute respiratory distress syndrome (ARDS), sepsis and septic shock, and multiorgan failure. This consensus document has been prepared on evidence-informed guidelines developed by a multidisciplinary panel of health care providers from four Spanish scientific societies (Spanish Society of Intensive Care Medicine [SEMICYUC], Spanish Society of Pulmonologists [SEPAR], Spanish Society of Emergency [SEMES], Spanish Society of Anesthesiology, Reanimation, and Pain [SEDAR]) with experience in the clinical management of patients with COVID-19 and other viral infections, including SARS, as well as sepsis and ARDS. The document provides clinical recommendations for the noninvasive respiratory support (noninvasive ventilation, high flow oxygen therapy with nasal cannula) in any patient with suspected or confirmed presentation of COVID-19 with acute respiratory failure. This consensus guidance should serve as a foundation for optimized supportive care to ensure the best possible chance for survival and to allow for reliable comparison of investigational therapeutic interventions as part of randomized controlled trials.
Copyright © 2020. Publicado por Elsevier España, S.L.U.

Keywords:  Aerosol-generating procedures; Control de infección; High-flow nasal therapy; Infection control; Non-invasive mechanical ventilation; Procedimientos generadores de aerosoles; Terapia nasal de alto flujo; Ventilación mecánica no invasiva

Mesh:

Year:  2020        PMID: 32336563      PMCID: PMC7270645          DOI: 10.1016/j.arbres.2020.03.005

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  3 in total

1.  Lung Ultrasound to Predict Unfavorable Progress in Patients Hospitalized for COVID-19.

Authors:  Cristina Ramos Hernández; Maribel Botana Rial; Luis Alberto Pazos Area; Marta Núñez Fernández; Silvia Pérez Fernández; Martín Rubianes González; Manuel Crespo Casal; Alberto Fernández Villar
Journal:  Arch Bronconeumol       Date:  2020-09-21       Impact factor: 4.872

2.  Screening in Lung Cancer: The Latest Evidence.

Authors:  Luis M Seijo; Juan Carlos Trujillo; Javier J Zulueta
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2019-06-13       Impact factor: 4.872

3.  RIBRON: The spanish Online Bronchiectasis Registry. Characterization of the First 1912 Patients.

Authors:  Miguel Angel Martinez-García; Carmen Villa; Yadira Dobarganes; Rosa Girón; Luis Maíz; Marta García-Clemente; Oriol Sibila; Rafael Golpe; Juan Rodríguez; Esther Barreiro; Juan Luis Rodriguez; Rosario Menéndez; Concepción Prados; David de la Rosa; Casilda Olveira
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2020-02-17       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.